Regardless of emerging literature and suggestive contributions of SMN and the role it plays in muscle and muscle development, the mechanisms and underlying muscle pathology in SMA are poorly understood which challenges providers seeking best treatments for resulting phenotypic presentations and the associated impairments affecting muscle, specifically contractures and altered muscle length. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.